Open-label pilot study of injectable naltrexone for cannabis dependence

References

• Quality CfBHSa. 2015 National Survey on Drug Use and Health: detailed Tables. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2016.
   Google Scholar
• Budney AJ, Roffman R, Stephens RS, Walker D. Marijuana dependence and its treatment. Addict Sci Clin Pract. 2007;4(1):4–16. doi:10.1151/ASCP07414.
   PubMedGoogle Scholar
• Kathmann M, Flau K, Redmer A, Trankle C, Schlicker E. Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors. Naunyn-Schmiedeberg’s Archiv Pharmacol. 2006;372(5):354–61. doi:10.1007/s00210-006-0033-x.
   PubMed Web of Science ®Google Scholar
• Manzanares J, Corchero J, Romero J, Fernandez-Ruiz JJ, Ramos JA, Fuentes JA. Pharmacological and biochemical interactions between opioids and cannabinoids. Trends Pharmacol Sci. 1999;20(7):287–94. doi:10.1016/S0165-6147(99)01339-5.
   PubMed Web of Science ®Google Scholar
• Cooper ZD, Haney M. Opioid antagonism enhances marijuana’s effects in heavy marijuana smokers. Psychopharmacol. 2010;211(2):141–48. doi:10.1007/s00213-010-1875-y.
   PubMed Web of Science ®Google Scholar
• Haney M. Opioid antagonism of cannabinoid effects: differences between marijuana smokers and nonmarijuana smokers. Neuropsychopharmacol. 2007;32(6):1391–403. doi:10.1038/sj.npp.1301243.
   PubMed Web of Science ®Google Scholar
• Haney M, Bisaga A, Foltin RW. Interaction between naltrexone and oral THC in heavy marijuana smokers. Psychopharmacol. 2003;166(1):77–85. doi:10.1007/s00213-002-1279-8.
   PubMed Web of Science ®Google Scholar
• Wachtel SR, De Wit H. Naltrexone does not block the subjective effects of oral Delta(9)-tetrahydrocannabinol in humans. Drug Alcohol Depend. 2000;59(3):251–60. doi:10.1016/S0376-8716(99)00127-1.
   PubMed Web of Science ®Google Scholar
• Greenwald MK, Stitzer ML. Antinociceptive, subjective and behavioral effects of smoked marijuana in humans. Drug Alcohol Depend. 2000;59(3):261–75. doi:10.1016/S0376-8716(99)00128-3.
   PubMed Web of Science ®Google Scholar
• Ranganathan M, Carbuto M, Braley G, Elander J, Perry E, Pittman B, Radhakrishnan R, Sewell RA, D'Souza DC. Naltrexone does not attenuate the effects of intravenous Delta9-tetrahydrocannabinol in healthy humans. Int J Neuropsychopharmacol. 2012;15(9):1251–64. doi:10.1017/S1461145711001830.
   PubMed Web of Science ®Google Scholar
• Paquette J, Olmstead MC. Ultra-low dose naltrexone enhances cannabinoid-induced antinociception. Behav Pharmacol. 2005;16(8):597–603. doi:10.1097/00008877-200512000-00001.
   PubMed Web of Science ®Google Scholar
• Bahremand A, Shafaroodi H, Ghasemi M, Nasrabady SE, Gholizadeh S, Dehpour AR. The cannabinoid anticonvulsant effect on pentylenetetrazole-induced seizure is potentiated by ultra-low dose naltrexone in mice. Epilepsy Res. 2008;81(1):44–51. doi:10.1016/j.eplepsyres.2008.04.010.
   PubMed Web of Science ®Google Scholar
• Tulunay FC, Ayhan IH, Portoghese PS, Takemori AE. Antagonism by chlornaltrexamine of some effects of delta 9-tetrahydrocannabinol in rats. Eur J Pharmacol. 1981;70(2):219–24. doi:10.1016/0014-2999(81)90217-X.
   PubMed Web of Science ®Google Scholar
• Solinas M, Goldberg SR. Involvement of mu-, delta- and kappa-opioid receptor subtypes in the discriminative-stimulus effects of delta-9-tetrahydrocannabinol (THC) in rats. Psychopharmacol. 2005;179(4):804–12. doi:10.1007/s00213-004-2118-x.
   Web of Science ®Google Scholar
• Braida D, Pozzi M, Parolaro D, Sala M. Intracerebral self-administration of the cannabinoid receptor agonist CP 55,940 in the rat: interaction with the opioid system. Eur J Pharmacol. 2001;413(2–3):227–34. doi:10.1016/S0014-2999(01)00766-X.
   PubMed Web of Science ®Google Scholar
• Navarro M, Carrera MR, Fratta W, Valverde O, Cossu G, Fattore L, Chowen JA, Gomez R, del Arco I, Villanua MA, Maldonado R, et al. Functional interaction between opioid and cannabinoid receptors in drug self-administration. J Neurosci. 2001;21(14):5344–50.
   PubMed Web of Science ®Google Scholar
• Justinova Z, Tanda G, Munzar P, Goldberg SR. The opioid antagonist naltrexone reduces the reinforcing effects of Delta 9 tetrahydrocannabinol (THC) in squirrel monkeys. Psychopharmacol. 2004;173(1–2):186–94. doi:10.1007/s00213-003-1693-6.
   PubMed Web of Science ®Google Scholar
• Raby WN, Carpenter KM, Rothenberg J, Brooks AC, Jiang H, Sullivan M, Bisaga A, Comer S, Nunes EV. Intermittent marijuana use is associated with improved retention in naltrexone treatment for opiate-dependence. Am J Addic. 2009;18(4):301–08.
   PubMed Web of Science ®Google Scholar
• Bisaga A, Sullivan MA, Glass A, Mishlen K, Pavlicova M, Haney M, Raby WN, Levin FR, Carpenter KM, Mariani JJ, Nunes EV. The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone. Drug Alcohol Depend. 2015;154:38–45. doi:10.1016/j.drugalcdep.2015.05.013.
   PubMed Web of Science ®Google Scholar
• Haney M, Ramesh D, Glass A, Pavlicova M, Bedi G, Cooper ZD. Naltrexone Maintenance Decreases Cannabis Self-Administration and Subjective Effects in Daily Cannabis Smokers. Neuropsychopharmacol. 2015;40(11):2489–98. doi:10.1038/npp.2015.108.
   PubMed Web of Science ®Google Scholar
• Benjamin D, Grant ER, Pohorecky LA. Naltrexone reverses ethanol-induced dopamine release in the nucleus accumbens in awake, freely moving rats. Brain Res. 1993;621(1):137–40. doi:10.1016/0006-8993(93)90309-B.
   PubMed Web of Science ®Google Scholar
• Lobmaier PP, Kunoe N, Gossop M, Waal H. Naltrexone depot formulations for opioid and alcohol dependence: a systematic review. CNS Neurosci Ther. 2011;17(6):629–36. doi:10.1111/j.1755-5949.2010.00194.x.
   PubMed Web of Science ®Google Scholar
• Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(Suppl 20):22–33; quiz 34-57.
   PubMed Web of Science ®Google Scholar
• Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62. doi:10.1136/jnnp.23.1.56.
   PubMed Web of Science ®Google Scholar
• Johnson BA, Ait-Daoud N, Roache JD. The COMBINE SAFTEE: a structured instrument for collecting adverse events adapted for clinical studies in the alcoholism field. J Stud Alcohol. 2005;Supplement(15):157–67. discussion 140. doi:10.15288/jsas.2005.s15.157.
   Google Scholar
• Robinson SM, Sobell LC, Sobell MB, Leo GI. Reliability of the Timeline Followback for cocaine, cannabis, and cigarette use. Psychol Addict Behav. 2014;28(1):154–62. doi:10.1037/a0030992.
   PubMed Web of Science ®Google Scholar
• Gray KM, Carpenter MJ, Baker NL, DeSantis SM, Kryway E, Hartwell KJ, McRae-Clark AL, Brady KT. A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. Am J Psychiatry. 2012;169(8):805–12. doi:10.1176/appi.ajp.2012.12010055.
   PubMed Web of Science ®Google Scholar
• Levin FR, Mariani JJ, Pavlicova M, Brooks D, Glass A, Mahony A, Nunes EV, Bisaga A, Dakwar E, Carpenter KM, Sullivan MA, et al. Dronabinol and lofexidine for cannabis use disorder: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend. 2016;159:53–60. doi:10.1016/j.drugalcdep.2015.11.025.
   PubMed Web of Science ®Google Scholar
• Mason BJ, Crean R, Goodell V, Light JM, Quello S, Shadan F, Buffkins K, Kyle M, Adusumalli M, Begovic A, Rao S. A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. Neuropsychopharmacol. 2012;37(7):1689–98. doi:10.1038/npp.2012.14.
   PubMed Web of Science ®Google Scholar
• Gray KM, Sonne SC, McClure EA, Ghitza UE, Matthews AG, McRae-Clark AL, Carroll KM, Potter JS, Wiest K, Mooney LJ, Hasson A, et al. A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults. Drug Alcohol Depend. 2017;177:249–57. doi:10.1016/j.drugalcdep.2017.04.020.
   PubMed Web of Science ®Google Scholar
• Gueorguieva R, Wu R, Pittman B, Cramer J, Rosenheck RA, O’Malley S, Krystal JH. New Insights into the Efficacy of Naltrexone Based on Trajectory-Based Reanalyses of Two Negative Clinical Trials. Biol Psychiatry. 2007;61(11):1290–95. doi:10.1016/j.biopsych.2006.09.038.
   PubMed Web of Science ®Google Scholar
• Dunbar JL, Turncliff RZ, Dong Q, Silverman BL, Ehrich EW, Lasseter KC. Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone. Alcohol Clin Exp Res. 2006;30(3):480–90. doi:10.1111/j.1530-0277.2006.00052.x.
   PubMed Web of Science ®Google Scholar
• Dundon WD, Pettinati HM, Lynch KG, Xie H, Varillo KM, Makadon C, Oslin DW. The therapeutic alliance in medical-based interventions impacts outcome in treating alcohol dependence. Drug Alcohol Depend. 2008;95(3):230–36. doi:10.1016/j.drugalcdep.2008.01.010.
   PubMed Web of Science ®Google Scholar
• Pettinati H, Weiss RD, Miller WR, Donovan D, Ernst DB, Rounsaville BJ, (ed.). Medical Management Treatment Manual: a Clinical Research Guide for Medically Trained Clinicians Providing Pharmacotherapy as Part of the Treatment for Alcohol Dependence. Bethesda, MD: Department of Health and Human Services; 2004.
   Google Scholar
• Krupitsky E, Nunes EV, Ling W, Gastfriend DR, Memisoglu A, Silverman BL. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness. Addic. 2013;108(9):1628–37. doi:10.1111/add.2013.108.issue-9.
   PubMed Web of Science ®Google Scholar